Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg R Pond

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
BMC Medical Research Methodology|December 14, 2011
Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trialsJohn R Goffin, Greg R Pond
BMC Medical Research Methodology|June 23, 2011
A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trialsJohn R Goffin, Greg R Pond, Dongsheng Tu
Palliative Medicine|December 4, 2018
Early initiation of palliative care is associated with reduced late-life acute-hospital use: A population-based retrospective cohort studyDanial Qureshi, Peter Tanuseputro, Richard Perez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimensMohammad I Zia, Lillian L Siu, Greg R Pond, et al.
Gynecologic Oncology|May 2, 2020
Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort studyLimor Helpman, Greg R Pond, Lorraine Elit, et al.
Journal of Geriatric Oncology|February 6, 2014
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trialAnne M Horgan, Bostjan Seruga, Greg R Pond, et al.
Clinical Breast Cancer|September 26, 2019
Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic InformationSusan J Robertson, Greg R Pond, John Hilton, et al.
The Journal of Urology|January 13, 2006
Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsyRobert K Nam, Ants Toi, John Trachtenberg, et al.
BMJ Open|May 27, 2022
Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysisShawn M Hercules, Meena Alnajar, Chen Chen, et al.
The Canadian Journal of Urology|May 5, 2006
Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancerRobert K Nam, Ants Toi, Laurence H Klotz, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
BMC Medical Research Methodology|December 14, 2011
Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trialsJohn R Goffin, Greg R Pond
BMC Medical Research Methodology|June 23, 2011
A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trialsJohn R Goffin, Greg R Pond, Dongsheng Tu
Palliative Medicine|December 4, 2018
Early initiation of palliative care is associated with reduced late-life acute-hospital use: A population-based retrospective cohort studyDanial Qureshi, Peter Tanuseputro, Richard Perez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimensMohammad I Zia, Lillian L Siu, Greg R Pond, et al.
Gynecologic Oncology|May 2, 2020
Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort studyLimor Helpman, Greg R Pond, Lorraine Elit, et al.
Journal of Geriatric Oncology|February 6, 2014
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trialAnne M Horgan, Bostjan Seruga, Greg R Pond, et al.
Clinical Breast Cancer|September 26, 2019
Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic InformationSusan J Robertson, Greg R Pond, John Hilton, et al.
The Journal of Urology|January 13, 2006
Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsyRobert K Nam, Ants Toi, John Trachtenberg, et al.
BMJ Open|May 27, 2022
Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysisShawn M Hercules, Meena Alnajar, Chen Chen, et al.
The Canadian Journal of Urology|May 5, 2006
Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancerRobert K Nam, Ants Toi, Laurence H Klotz, et al.
Pageof 2